PCOS (Polycystic Ovarian Syndrome) Patients

Prospective Cohort Study for PCOS Patients in Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03991507

Enrollment

10000

Registered

2019-06-19

Start date

2010-01-01

Completion date

2050-12-31

Last updated

2019-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Related

Brief summary

The Prospective Cohort Study for PCOS Patients was set up to investigate the short- and long-term health consequences in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, China.

Detailed description

Polycystic ovary syndrome (PCOS) affects 8-13% of women. It is a multifaceted condition characterized by chronic anovulation and excess ovarian activity. Since last decade, Clinical Reproductive Medicine Management System/Electronic Medical Record Cohort Database (CCRM/EMRCD) has been used in Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University, and Henan Province Key Laboratory for Reproduction and Genetics. Information of patients (POI, PCOS, Endometriosis, azoospermia, ect) were recorded comprehensively. The current project plans to recruit PCOS participants in our center. Biological samples, questionnaires and short/long term health data will be collected. The study is aimed to provide evidence for PCOS prognosis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* PCOS patients diagnosed with The Rotterdam diagnostic criteria.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Level of serum FSH (Follicle stimulating hormone)	From date of inclusion, assessed by each 12 month, up to 40 years	mIU/mL
Level of serum LH (Luteinizing hormone)	From date of inclusion, assessed by each 12 month, up to 40 years	mIU/mL
Level of T (Testosterone)	From date of inclusion, assessed by each 12 month, up to 40 years	ng/ml

Secondary

Measure	Time frame	Description
Body Weight	From date of inclusion, assessed by each 12 month, up to 40 years	Recorded in Kilograms
Height	From date of inclusion, assessed by each 12 month, up to 40 years	Recorded in centimeters

Countries

China

Contacts

Primary ContactLanlan Fang, M.D.

fanglly@163.com13673355291

Outcome results